title: Gonadal status and body mass index jointly determine growth hormone (GH)-releasing hormone/GH-releasing peptide synergy in healthy men.
abstract: BACKGROUND
  Sex steroid hormones potentiate whereas increased body mass index (BMI) represses GH secretion. Whether sex steroids modify the negative effect of BMI on secretagogue-induced GH secretion in men is not known. The issue is important in designing GH-stimulation regimens that are relatively insensitive to both gonadal status and adiposity.
  
  
  OBJECTIVE
  Our objective was to compare the relationships between BMI and peptide-stimulated GH secretion in men with normal and reduced testosterone and estradiol availability.
  
  
  METHODS
  The study was performed at an academic medical center.
  
  
  METHODS
  Healthy young men were included in the study.
  
  
  METHODS
  Randomized separate-day iv infusion of saline and/or maximally effective doses of L-arginine/GHRH, L-arginine/GH-releasing peptide (GHRP)-2, and GHRH/GHRP-2 in eugonadal (n=12) and experimentally hypogonadal (n=10) men was performed.
  
  
  RESULTS
  Regression of paired secretagogue-induced GH responses on BMI was determined.
  
  
  RESULTS
  In eugonadal men, peak GH concentrations correlated negatively with BMI. In particular, BMI accounted for only 38% of the response variability after L-arginine/GHRH (P=0.0165), but 62% after GHRH/GHRP-2 (P=0.0012) and 65% after L-arginine/GHRP-2 (P=0.00075). In contrast, in hypogonadal men, GH responses were uncorrelated with BMI. The negative effects of BMI on peak GH responses in eugonadal and hypogonadal states differed most markedly after stimulation with GHRH/GHRP-2 (P=0.0019). This contrast was corroborated using integrated GH responses (P=0.0007).
  
  
  CONCLUSIONS
  Short-term experimental gonadal sex hormone depletion attenuates dual secretagogue-stimulated GH secretion in lean young men. The inhibitory effect of relative adiposity on GH secretion appears to predominate over that of acute sex steroid withdrawal.
authors: Department of Pediatrics, Endocrine Research Unit, Clinical Translational Research Center, Mayo Medical and Graduate Schools, Mayo Clinic, Rochester, Minnesota 55901, USA.
authors: Remberto C
authors: RC
authors: Paulo
authors: Mihaela
authors: M
authors: Cosma
authors: Cacia
authors: C
authors: Soares-Welch
authors: Joy N
authors: JN
authors: Bailey
authors: Kristi L
authors: KL
authors: Mielke
authors: John M
authors: JM
authors: Miles
authors: Cyril Y
authors: CY
authors: Bowers
authors: Johannes D
authors: JD
authors: Veldhuis
mesh_terms: D000328:Adult; D001120:Arginine / Q000494:pharmacology; D015992:Body Mass Index; D004357:Drug Synergism; D013007:Growth Hormone-Releasing Hormone / Q000494:pharmacology*; D019382:Human Growth Hormone / Q000378:metabolism*; D006801:Humans; D007006:Hypogonadism / Q000378:metabolism*; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology*
chemical_list: D009842:Oligopeptides; D019382:Human Growth Hormone; D013007:Growth Hormone-Releasing Hormone; D001120:Arginine; C091874:growth hormone-releasing peptide-2